MISSOURI BIOTECHNOLOGY ASSOCIATION - WHAT WE DO
Missouri Biotechnology Association (MOBIO) is the only statewide membership group that speaks with one voice to advance and champion the life sciences in Jefferson City, across the state, and in Washington, D.C. MOBIO represents most extensive and broadest cross-section of life science organizations including businesses, higher education, medical research, start-ups, agri-science and related firms involved in research, development, and commercialization of the life sciences. MOBIO serves to connect, develop, and advance the state’s bioscience community.
MOBIO members benefit from a strategic focus to support the enrichment and growth of the biosciences in Missouri through:
MOBIO connections make a difference, specializing in meaningful business-to-business engagements and bridging:
- A network of diversified thought leaders
- Business leaders with policymakers
- Entrepreneurs with investors
- Members to greater market potential
Members connect at regional, national, and international levels with science, education, and commercial networks to advance business and enrich the industry.
MOBIO is the catalyst, accelerating growth and leveraging high-value relationships for our vibrant life sciences community.
Science & Policy
MOBIO advocates for Missouri’s life sciences and technology sectors. Maintaining a sophisticated understanding of current dynamics, MOBIO serves as your trusted voice for bipartisan engagement and leadership within the Missouri State Capitol.
- MOBIO forges meaningful relationships between public and private sector leaders to:
- Defend companies large and small
- Obtain and safeguard public investment
- Secure state funding for Missouri's life science industry
The strength of MOBIO's collective voice consistently delivers a compelling message to advance pro-science, pro-business legislative policy.
MOBIO saves members real money, providing access to numerous partner organizations that offer significant discounts on relevant industry products and services.
- R & D
- Finance & Administration
- Facilities & Operations
- Communications & Data
All MOBIO members are entitled to preferred purchasing power. There is NO fee to participate.
MOBIO Member Highlight
Phage display has revolutionized modern basic and biomedical research, leading to groundbreaking innovations recognized with the 2018 Nobel Prize in Chemistry. Dr. George Smith of the University of Missouri was one of the recipients of this Nobel Prize whose pioneering work set a strong foundation for drug discovery using phage display technology. His achievement has prompted much pride amongst both local Columbian residents as well as the University of Missouri.
For Cell Origins COO Jessica Newton-Northup, who has been trained by Dr. George Smith and Dr. Susan Deutscher at Mizzou, it provides an opportunity to grow and establish a foothold in the phage display market. The scientists at Cell Origins bring their extensive experience and expertise to provide services that include peptide and antibody discovery, screening, and method development, as well as premade and customized phage display libraries for customers seeking to develop diagnostic or therapeutic peptides and antibodies.The drug discovery process poses a number of challenges that must be overcome to develop successful therapeutics. Challenges typically arise from the difficulty of developing peptides and antibodies with all the necessary characteristics to create an effective drug product such as high binding affinity, specificity for the biomarker target, and sufficient stability and solubility. Additionally, the pharmacokinetics of the drug must be developed to ensure desired tissue concentrations while minimizing systemic exposure. To effectively address these obstacles, each drug discovery program must be specifically tailored to bring successful therapeutic and diagnostic peptide and antibody products to market. "What makes Cell Origins unique in the peptide and antibody discovery space, is our custom approach that combines multi-tier phage display selections", says Dr. Mette Soendergaard (CSO). The scientists at Cell Origins also use their deep understanding of molecular targets, disease mechanisms, and pharmacokinetic properties to provide peptides and antibodies with superior characteristics. Jessica Newton-Northup adds "We specialize in tough challenges like small epitopes and biomarkers that have proven difficult to target by others".Cell Origins is a 100% women-owned business that is operated in Mid-Missouri. The three owners are alumni of the University of Missouri and owe their friendships and business relationships to the university. It was through Mizzou that Leann Qi (CEO), Jessica Newton-Northup (COO), and Dr. Mette Soendergaard (CSO) joined forces to submit a small business innovation research (SBIR) grant, which formed the foundation of Cell Origins. With this strong foundation, the three Mizzou alumni were able to expand into the many phage display services that the company now offers."Our original SBIR grant focused on the use of phage display to develop a method to discern phenotypic changes in human cell lines as a result of different culturing conditions", says Jessica Newton-Northup (COO). This NIH program announcement focused on the development of products able to help the scientific community better standardize and control the myriad of variables inherent to all work with cultured mammalian cells. Most of the proposed protocols for the identification and quality control of laboratory cell lines focus on a single aspect of cell biology or upon documentation. These approaches cannot generate a broad biochemical profile of a cell line and consequently cannot monitor a cell line for phenotypic changes. Thus, the scientific community continues to produce cultured cell-based data without controls for many ill-defined variables. "At Cell Origins, we are, however, actively working on the development of a unique proprietary product able to dually target both mRNA and cell surface phenotypic biomarkers of any composition", says Dr. Mette Soendergaard (CSO). The method can, in concert with Short Tandem Repeat (STR) analysis, probe three tiers of cell biology; DNA, RNA, and cell surface biomarkers. Cell Origin's phage display-selected biomarkers are able to provide initial evidence of changes due to cell age, passage number, media composition, and culture conditions. The scientific community will gain valuable insight from this new product, which can be used to accurately identify cells, adjust culture conditions, and assess data for reproducible results.Phage display has become a powerful tool in drug discovery, and the owners of Cell Origins are excited about the future of the peptide and antibody drug discovery market. "The global peptide therapeutics market is estimated to reach an impressive value of nearly $62 billion by 2027, with a remarkable 9.42% compound annual growth rate (CAGR)', says LeAnn Qi (CEO). The North American market for peptide-based cancer therapeutics is experiencing exponential growth, driven by the FDA approval of treatments such as Lutathera and increased investment from pharmaceutical giants. Cell Origins is continuously advancing phage display strategies to provide pharmaceutical companies and academic laboratories with support in their drug discovery projects. For more information please visit our website: cellorigins.com
Join us for MOBIO's Breakthrough of the Month series, where we explore Missouri's new and sometimes hidden biotech industry.
This is a virtual learning platform for the greater life science community where we highlight and discuss novel discoveries, new business opportunities, and potential partnerships.
This is a FREE presentation that is open to those in the life-science community.
Are you interested in featuring your organization or discovery? Please reach out to us, via email.